Track topics on Twitter Track topics that are important to you
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Companyâs targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQuleâs lead product, in Phase 2 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase. The Company is also conducting Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. The Companyâs pre-clinical pipeline includes a compound designed to inhibit the B-RAF kinase. ArQuleâs current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIPâ¢), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase. The most advanced AKIPâ¢ program is focused on the discovery of inhibitors of fibroblast growth factor receptor (FGFR).
WASHINGTON (dpa-AFX) - Biopharmaceutical company ArQule, Inc. (ARQL) announced Tuesday that the first patient has been dosed in a phase 1a/b trial with its BTK inhibitor, ARQ 531, in patients with...
US-based biopharmaceutical firm ArQule has begun dosing patients with ARQ 092 in a Phase I/II clinical trial to treat patients with rare overgrowth diseases.
Trial is enrolling patients refractory to standard of care, including ibrutinib BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient ...
ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter 2017 before the market opens on Friday, August 4, 2017. The Company will...
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, M.D., Head of Research and Development and Chief Medical Officer, wi...
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Companyâs targeted, broad-spectrum produ...
On December 19, 2008, ArQule and Daiichi Sankyo, Co., Ltd. signed a license, co-development and co-commercialization agreement to co-develop tivantinib in the U.S., Europe, South ...
ArQule has created a new technology platform for the discovery and production of novel chemical compounds with commercial potential. The Company has developed proprietary technologies for the identifi...
We have published hundreds of ArQule, Inc. news stories on BioPortfolio along with dozens of ArQule, Inc. Clinical Trials and PubMed Articles about ArQule, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ArQule, Inc. Companies in our database. You can also find out about relevant ArQule, Inc. Drugs and Medications on this site too.
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...